



STUDY OF FSH & LH CHANGES IN COVID-19 PATIENTS

Physiology

Nataraj Singh

Loukrakpam

Rajima Sahani

Govindaraj Singh

Yengkhom

KEYWORDS

INTRODUCTION:-

Coronaviruses are large, roughly spherical particles with unique surface projections¹. Coronaviruses constitute the subfamily Orthocoronavirinae, in the family Coronaviridae, order Nidovirales and realm Riboviria². They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry³. Size of coronaviruses ranges from approximately 26 to 32 kilobases⁴. Human-to-human transmission of SARS-CoV-2 was confirmed on 20 January 2020 during the COVID-19 pandemic⁵. Recently, the WHO reported the possibility of airborne transmission, as well as the presence of RNA in urine and semen, increasing the possibility of sexual transmission⁶. Since the 1918 flu pandemic, the novel coronavirus disease COVID-19 has become the fifth documented pandemic till date.

SARS-CoV-2 was first reported in Wuhan City of Hubei Province of China on 17th November 2019⁷ and subsequently spreads to 212 countries and territories around the globe infecting millions of people. Almost all countries throughout the world reported the disease spread caused by aerosol penetration into the upper respiratory tract and lungs via inhalation⁸. The World Health Organisation (WHO) declared a public health emergency of international concern on 30th January 2020 and a Pandemic on 11th March 2020.

SARS-CoV-2 has four proteins, spike, membrane, small membrane proteins and nucleocapsid. The S protein is essential for the virus to fuse to the host cell through the receptor-binding-domain⁹. The key pathway for SARS-CoV-2 to enter the cell is through the S-protein attachment to the angiotensin-converting enzyme 2 (ACE2), which is highly expressed in spermatogenic stem cells, seminiferous duct cells, type II alveolar cells, myocardial cells, bladder urothelial cells and proximal tubule cells¹⁰. Recently reported that SARS-CoV-2 virus critically depends on angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease (TMPRSS2 and TMPRSS4), as a receptor to enter cells¹¹.

As of 20th June 2022, the pandemic has infected more than 540 million cases and 6.32 million confirmed deaths, making it one of the deadliest in history. First case of COVID-19 in India was reported on 30th January 2020. The first case was reported on 24th March 2020 in Manipur. As of 20th June 2022 around 1, 37, 247 cases has been reported along with 2120 deaths from Covid related illness in Manipur. According to WHO, "Post COVID-19 are those conditions occurring in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms last for at least 2 months. Common symptoms include fatigue, shortness of breath, fatigue, cough, cognitive dysfunction but also others that impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time."

Post-COVID syndrome, also known as long-COVID, was described as a clinical entity for the first time in spring of 2020, when COVID-19 patients still had symptoms several weeks after their acute infection¹². Although there are indications that the evolution of post-COVID syndrome is driven by cytokines, research is needed to elucidate its pathogenesis¹³.

The incidence of post-COVID sequelae is estimated between 10 and 35%¹⁴. Fatigue, shortness of breath, chest pain, mental disorders, olfactory and gustatory dysfunction are amongst the most common symptoms^{15,16}. Unfortunately, about 3.6% patients sadly died of multiple organ failure, acute respiratory distress syndrome, shock, heart, or renal failure. Majority of those infected are still alive, although with organ damage, e.g in the reproductive system, especially in those reproductive age women¹⁷ who would likely have sought to become pregnant without concern for related gynaecological complications¹⁸. Besides the self-reported menstrual cycle changes, ovarian reserve markers and reproductive hormones, including anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), the ratio of FSH to luteinizing hormone (LH), estradiol (E2), progesterone (P), testosterone (T), and prolactin (PRL), should be an effective way to reflect the ovarian function^{19,20} and possible ovarian injury associated with the COVID-19 diseases.

LH and FSH are the hormones secreted from pituitary gland. At the beginning of the menstrual cycle, LH and FSH levels usually range between about 5-20 mIU/ml. During the early part of their menstrual cycle most women have about equal amounts of LH and FSH. During LH surge amount of LH increases to about 25-40 mIU/ml 24 hours before ovulation occurs. Once the ova are released by the ovarian, the LH levels back down²¹.

Menstruation is the cyclic, orderly sloughing of the uterine lining, in response to the interactions of hormones produced by the hypothalamus, pituitary, and ovaries. The menstrual cycle may be divided into different phases – 1. Follicular/ Preovulatory phase: Day 1-5: Menstruation (period) Day 6-14: Follicular growth and estrogen increase. Ovulation occurs around day 14 (release of an egg from the ovary). 2. Ovulatory phase: Day 14-17: Ovulation and peak estrogen levels. 3. Luteal phase: Day 18-28: Corpus luteum forms (empty follicle in the ovary) and progesterone increases. The uterine lining thickens, preparing for a fertilized egg. If the egg isn't fertilized, the corpus luteum breaks down, and menstruation occurs. The average duration of a menstrual cycle is 28 days with most cycle lengths between 25 to 30 days

Various studies have shown that COVID-19 vaccination and SARS-CoV-2 infection temporarily altered menstrual cycles^{22,23,24}, but there was not much research on COVID-19 infection and changes in menstruation. As more concerns has emerged regarding the effects of the novel Coronavirus on pregnancy outcomes and menstrual changes, determination of serum FSH and LH level during Preovulatory phase in Post-Covid females of reproductive age group and evaluate the association of serum FSH and LH during Pre-Ovulatory phase and Menstrual cycle might help in providing more insights on the effect of novel Coronavirus in females of reproductive age group.

MATERIALS & METHODS:-

Study Design: Cross sectional study

Study Setting: The study will be carried out in the Department of Physiology, Regional Institute of Medical Sciences, Imphal, Manipur.

Duration Of Study: 2 years (October 2022 to September 2024)

Study Population: 18 to 45 years of age females who recovered from Covid-19 infection of Imphal East and Imphal West.

Ethical Issues:- The study was carried out after getting clearance from

the Institutional Ethics Committee, Regional Institute Of Medical Sciences, Imphal.


Inclusion Criteria:

1. Females of 18 to 45 years of age who had recovered from covid - 19 infection

Exclusion Criteria:

1. Those who are suffering from PCOS, DUB, Fibroid, Infertility, Thyroid Disease
2. Those who are taking OCP drugs
3. Those who are under any Hormonal therapy
4. Those who are pregnant during study
5. Those who are lactating during study
6. Those who are suffering from any systemic illness
7. Those who had consumed Stevia, caffeine, soy products, dairy products in excess quantity


RESULTS & OBSERVATIONS:-



FSH (Follicle-Stimulating Hormone) Levels

The FSH levels among the patients are nearly equally split between the 1.4-9.9 range and the >9.9 range, each accounting for 49.53% (104 patients). A small minority, 0.96% (2 patients), have FSH levels below 1.4. This distribution indicates a varied hormonal profile within the patient sample.


FSH	No of Patients (%)
<1.4	2 (0.96%)
1.4-9.9	104 (49.53%)
>9.9	104 (49.53%)
Total	210 (100%)



LH (Luteinizing Hormone) Levels

The LH levels show that 43.81% of patients (92 individuals) have LH levels greater than 14.6, while 41.43% (87 patients) fall within the 1.9-14.6 range. A smaller portion, 14.77% (31 patients), have LH levels below 1.9. This suggests a slightly higher prevalence of elevated LH levels among the patients.

LH	No of Patients (%)
<1.9	31 (14.77%)
1.9-14.6	87 (41.43%)
>14.6	92 (43.81%)
Total	210 (100%)



DISCUSSION:-

OUR study found that 49.53% of patients had FSH levels within 1.4-9.9 mIU/ml, the LH levels 1.9- 14.6 range was only observed for 41.43%. This suggests a slightly higher prevalence of elevated LH levels among the patients. Covid- 19 patients are often overlooked, yet abnormalities have been noted. Our study was aimed to assess the association of these hormones. It was observed that more than half of the study population had abnormal values for both FSH(50.5%) and LH (58.85%). Similarly other studies exhibited elevated levels of FSH & LH indicating potential ovarian suppression linked to Covid-19 (Li K 2021 & Moradi F et al.,2020). During times of stress, ovarian function can be suppressed to prioritize other essential organ systems, potentially leading to infertility and reduced menstruation in Covid-19 patients. This correlation underscores the observed menstrual changes in patients with severe multi-organ involvement, as documented in clinical studies.

CONCLUSION:-

The current COVID-19 pandemic had a devastating consequence all around the globe. Not only the physical and mental health has been affected but some literature has also reported of deranged ovarian functions. As more concerns has emerged regarding the effects of the novel coronavirus on pregnancy outcomes and menstrual changes.

REFERENCES:-

1. Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA, Lee WW et al. (February 2004). "Ultrastructural characterization of SARS coronavirus". *Emerging Infectious Diseases*. 10 (2): 320–6.
2. Fan Y, Zhao K, Shi ZL, Zhou P (March 2019). "Bat Coronaviruses in China". *Viruses*. 11 (3): 210.
3. Cherry J, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ (2017). *Feigin and Cherry's Textbook of Pediatric Infectious Diseases*. Elsevier Health Sciences. p. PT6615. ISBN 978-0-323-39281-5.
4. Woo PC, Huang Y, Lau SK, Yuen KY (August 2010). "Coronavirus genomics and bioinformatics analysis". *Viruses*. 2 (8): 1804–20.
5. Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, Ge XY (March 2020). "The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future". *Microbes and Infection*. 22 (2): 80–85.
6. Mali AS, Magdum M, Novotny J. COVID-19 impact on reproduction and fertility. *JBRA Assist Reprod*. 2021 Apr 27;25(2):310-313.
7. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020 Feb 15; 395(10223):470-73.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506.
9. Monteleone PA, Nakano M, Lazar V, Gomes AP, Martin H, Bonetti TC. A review of initial data on pregnancy during the COVID-19 outbreak: implications for assisted reproductive treatments. *JBRA Assist Reprod*. 2020;24:219–225.
10. Male V. COVID-19 vaccination and menstruation. *Sci (New York NY)* 2022;378(6621):704–6.
11. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395:565–574.
12. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727–733.
13. Greenhalgh T, Knight M, A'Court M. Management of post-acute covid-19 in primary care. *BMJ*. 2020;370:m3026.
14. Bhavana V, Thakor P, Singh SB. COVID-19: pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV-2 pandemic. *Life Sci*. 2020;2020(261).
15. Alpert O, Begun L, Gerren P. Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines – two case reports. *Brain Behav Immun Health*. 2020;9.
16. Tenforde M, Kim S, Lindsell C. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:993–998.
17. Huang C, Huang L, Wang Y. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397: 220–232.
18. Simani L, Ramezani M, Darazam IA. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *J Neurovirol*. 2021;27:154–159.
19. Tesarik J. After corona: there is life after the pandemic. *Reprod Biomed Online*. (2020) 40:760–2.
20. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220–32.
21. Male V. COVID-19 vaccination and menstruation. *Sci (New York NY)* 2022;378(6621):704–6.
22. Danesh L, Ali A, Aslam I, Mensah-Djan A. The effects of SARS-CoV-2 on menstruation. *Reprod Biomed Online*. 2021;43(4):769.
23. Farland LV, Khan SM, Shilen A, Heslin KM, Ishimwe P, Allen AM, Herbst-Kralovetz MM, Mahnert ND, Pogreba-Brown K, Ernst KC et al. COVID-19 vaccination and changes in the menstrual cycle among vaccinated persons. *Fertil Steril* 2022.
24. 157. Gulab K., Neelam N., Monika S, and Nidhi S. Serum Ghrelin, LH and FSH Concentrations During Menstrual Cycle in Non-Obese PCOS Women Compared to Healthy Women. *Dent. Med Sci*. 2015;14(5):64-68.
25. Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, Lee S, Wang C, Li H, Cheng L, Ai J. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. *Reprod Biomed Online*. 2021 Jan;42 (1):260-267.
26. Ding T, Wang T, Zhang J, Cui P, Chen Z, Zhou S, Yuan S, Ma W, Zhang M, Rong Y, Chang J, Miao X, Ma X, Wang S. Analysis of Ovarian Injury Associated With COVID-19 Disease in Reproductive-Aged Women in Wuhan, China: An Observational Study. *Front Med (Lausanne)*. 2021 Mar 19;8:635255.
27. Mahmud R, Rahman MM, Rassel MA, Monayem FB, Sayeed SKJB, Islam MS, et al. (2021) Post-COVID-19 syndrome among symptomatic COVID-19 patients: A

- prospective cohort study in a tertiary care center of Bangladesh. PLoS ONE 16(4): e0249644. <https://doi.org/10.1371/journal.pone.0249644>
28. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect.* 2021 Jan;27(1):89-95.
 29. Hannah E. Davis, Gina S. Assaf, Lisa McCorkell, Hannah Wei, Ryan J. Low, Yochai Re'em, Signe Redfield, Jared P. Austin, Athena Akrami, Characterizing long COVID in an international cohort: 7 months of symptoms and their impact, *EClinicalMedicine*, 2021, 38, 101019, ISSN 2589-5370 .
 30. Phelan N, Behan LA, Owens L. The Impact of the COVID-19 Pandemic on Women's Reproductive Health. *Front Endocrinol (Lausanne)*. 2021 Mar 22;12: 642755.
 31. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J et al. Potential Influence of Menstrual Status and Sex Hormones on Female Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Cross-sectional Multicenter Study in Wuhan, China. *Clin Infect Dis.* 2021 May 4;72(9):e240-e248.